Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
Move aligns global biologics identity under the Biocon Biologics brand
Board approves five-year appointment, subject to shareholder nod through postal ballot
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Subscribe To Our Newsletter & Stay Updated
